Enclomiphene vs testosterone
One is a DEA Schedule III controlled substance available in a limited set of states. The other is not controlled and prescribable everywhere. For an operator that difference is the whole business case.
Key takeaways
- Testosterone is DEA Schedule III. Enclomiphene is not a controlled substance.
- Scheduled testosterone is available in a limited subset of states, commonly with an age floor around 25.
- Enclomiphene is prescribable in all 50 states and D.C., typically from 18.
- Testosterone generally requires a synchronous visit before the first prescription. Enclomiphene generally does not.
- Carrying both means routing a patient rather than declining them, which is the commercial point.
Why scheduling changes everything
Testosterone's status as a DEA Schedule III controlled substance is not a detail. It drives a synchronous initial visit rather than asynchronous review, a narrower state map, a higher age floor, and renewal requirements tied to current lab results.
Enclomiphene is not a controlled substance. It still carries lab requirements and still requires a licensed provider in the patient's state, but it can generally run on asynchronous review, and it is prescribable across all 50 states and D.C.
The state map is the commercial difference
A men's health brand offering only scheduled testosterone declines traffic in every state where it cannot serve. That traffic was already paid for.
Carrying enclomiphene as a second pathway converts those patients instead. The intake detects the patient's state and profile and routes them to whichever pathway is available to them, rather than ending the flow.
For a national brand buying national traffic, this is often the single largest addressable-market decision in the category.
| Testosterone | Enclomiphene | |
|---|---|---|
| DEA scheduling | Schedule III | Not controlled |
| State availability | Limited subset | All 50 plus D.C. |
| Initial visit | Synchronous | Generally async with labs |
| Typical age floor | Around 25 | 18 |
| Baseline labs | Required | Required |
| Ongoing monitoring | Quarterly | Quarterly |
What stays the same
Both pathways require baseline labs before the first prescription and ongoing monitoring afterwards. Both require a provider licensed in the patient's state. Both should gate renewals on current lab results rather than on the patient continuing to pay.
The clinical seriousness is comparable. What differs is the regulatory machinery around delivering it.
Building for both without two workflows
The requirement is that one intake handles both, detecting state and profile and routing accordingly, rather than running two disconnected programmes your operations team has to keep straight.
Anastrozole and gonadorelin can be layered onto either protocol where the provider judges it appropriate, which is a catalog and formulary question rather than a workflow one.
Both pathways, chosen by the intake
PharmaBro supports both the scheduled testosterone and non-scheduled enclomiphene pathways, with intake detecting the patient's state and profile and routing to whichever is available to them.
Labs are ordered in-flow, results return to the patient record, and renewals are gated structurally on current results rather than tracked manually.
Conclusion
For a men's health brand this is less a clinical comparison than a coverage strategy.
Scheduled testosterone is the deeper product in the states where it is available. Enclomiphene is what lets you operate nationally. Carrying both, with the intake choosing, is how you stop declining traffic you already paid to acquire.
Frequently asked questions
Is enclomiphene a controlled substance?
No. Enclomiphene is not a DEA-scheduled substance, which is why it is prescribable in all 50 states and D.C. and can generally run on asynchronous review with labs, unlike scheduled testosterone.
Why is testosterone unavailable in some states?
Because it is DEA Schedule III, and state-level rules around prescribing controlled substances via telehealth vary. Availability changes with regulation, which is why routing should be driven by current state logic rather than a static list.
Do both require labs?
Yes. Both pathways require baseline labs before the first prescription and ongoing monitoring, and renewals should be gated on current results in both cases.
References
Priya RaghunathanHead of Compliance Operations
Handles LegitScript, HIPAA posture, MSO structuring and state coverage. Writes the parts of this blog that operators wish someone had told them before they signed.